GlobeNewswire: Cellect Biotechnology Ltd. Contains the last 10 of 20 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:10:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/05/03/976746/0/en/Cellect-Gets-Green-Light-From-FDA-For-ApoGraft-IND-Submission-in-the-U-S.html?f=22&fvtc=4&fvtv=29256Cellect Gets Green Light From FDA For ApoGraft IND Submission in the U.S.2017-05-03T11:01:00Z<![CDATA[Cellect’s CEO, Dr. Shai Yarkoni commented “The U.S. market is key for our planned commercial expansion and this will allow us to work tightly with the top U.S. institutes and global pharma companies on enabling stem cells for regenerative medicine.” Cellect’s CEO, Dr. Shai Yarkoni commented “The U.S. market is key for our planned commercial expansion and this will allow us to work tightly with the top U.S. institutes and global pharma companies on enabling stem cells for regenerative medicine.”]]>https://www.globenewswire.com/news-release/2017/04/03/953419/0/en/Cellect-Receives-Notice-of-Intention-to-Grant-from-European-Patent-Office-for-Patent-Protecting-Company-s-Technology-in-Multiple-Indications.html?f=22&fvtc=4&fvtv=29256Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology in Multiple Indications2017-04-03T10:02:00Z<![CDATA[Patent to provide coverage in both U.S. and EU]]>https://www.globenewswire.com/news-release/2017/03/27/945317/0/en/Cellect-Announces-Successful-First-Cancer-Patient-Stem-Cell-Transplant.html?f=22&fvtc=4&fvtv=29256Cellect Announces Successful First Cancer Patient Stem Cell Transplant 2017-03-27T11:02:00Z<![CDATA[Cellect’s technology, ApoGraft™, aims to become a game changer in stem cells transplantations for cancer treatments]]>https://www.globenewswire.com/news-release/2017/03/23/943440/0/en/Cellect-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2016-Financial-Results.html?f=22&fvtc=4&fvtv=29256Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results2017-03-23T11:05:00Z<![CDATA[TEL AVIV, Israel, March 23, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the fourth quarter and full year ended December 31, 2016.]]>https://www.globenewswire.com/news-release/2017/03/02/930016/0/en/Michael-Berelowitz-MD-Former-Head-Clinical-Development-and-Medical-Affairs-Pfizer-Specialty-Care-Business-Unit-Joins-Cellect-s-Board-of-Directors.html?f=22&fvtc=4&fvtv=29256Michael Berelowitz MD., Former Head, Clinical Development and Medical Affairs, Pfizer Specialty Care Business Unit Joins Cellect’s Board of Directors2017-03-02T12:01:00Z<![CDATA[TEL AVIV, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, today announced the appointment of Dr. Michael Berelowitz to the Company’s Board of Directors. Cellect’s Board now includes seven members, five of whom are independent.]]>https://www.globenewswire.com/news-release/2017/02/23/927127/0/en/Cellect-to-Ring-the-NASDAQ-Stock-Market-Opening-Bell-on-Friday-February-24th.html?f=22&fvtc=4&fvtv=29256Cellect to Ring the NASDAQ Stock Market Opening Bell on Friday, February 24th2017-02-23T16:00:00Z<![CDATA[TEL AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, announced today that the Company will ring The Nasdaq Stock Market Opening Bell at the Nasdaq MarketSite in Times Square on Friday, February 24, 2017.  The bell ringing ceremony will commemorate Cellect’s initial listing on the Nasdaq Stock Market, which occurred in the second half of 2016.]]>https://www.globenewswire.com/news-release/2017/02/23/926909/0/en/World-Renowned-Stem-Cell-Transplantation-Expert-joins-Cellect-s-Advisory-Board.html?f=22&fvtc=4&fvtv=29256World-Renowned Stem Cell Transplantation Expert joins Cellect’s Advisory Board2017-02-23T12:00:00Z<![CDATA[Dr. Cutler commented: “Cellect presents an opportunity to truly participate in a medical revolution. I am excited to be a part of it.” Dr. Cutler commented: “Cellect presents an opportunity to truly participate in a medical revolution. I am excited to be a part of it.”]]>https://www.globenewswire.com/news-release/2017/02/21/925788/0/en/Cellect-Announces-Positive-Clinical-Trial-Results.html?f=22&fvtc=4&fvtv=29256Cellect Announces Positive Clinical Trial Results2017-02-21T12:01:00Z<![CDATA[ApoGraft TM, Cellect’s flagship technology, validated as safe, robust and reproducible process for clinical use after a 104 donor test base]]>https://www.globenewswire.com/news-release/2017/02/14/917131/0/en/Dual-Listed-Cellect-to-Voluntarily-File-for-Delisting-from-Tel-Aviv-Stock-Exchange.html?f=22&fvtc=4&fvtv=29256Dual-Listed Cellect to Voluntarily File for Delisting from Tel Aviv Stock Exchange2017-02-14T21:01:00Z<![CDATA[Company’s Securities to Continue Trading Only on NASDAQ Stock Exchange in US Company’s Securities to Continue Trading Only on NASDAQ Stock Exchange in US]]>https://www.globenewswire.com/news-release/2017/02/08/915062/0/en/First-Cancer-Patient-Treated-In-Phase-I-II-Trial-of-ApoGraft.html?f=22&fvtc=4&fvtv=29256First Cancer Patient Treated In Phase I/II Trial of ApoGraft™2017-02-08T12:05:00Z<![CDATA[Management expects additional positive upcoming results from its trial in healthy volunteers]]>